No Data
No Data
QIAGEN N.V. to Release Results for Q2 2024 and Hold Webcast
Venlo, The Netherlands, July 02, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the second quarter 2024. Press release date / time: Wednesday,
Street Calls of the Week: Stifel Initiates on Tesla; Downgrade for Alphabet
Qiagen Upgraded at Wolfe on Valuation Discount
Qiagen Raised to Outperform From Peer Perform by Wolfe Research
Qiagen Raised to Outperform From Peer Perform by Wolfe Research
Wolfe Research Upgrades Qiagen NV(QGEN.US) to Buy Rating, Announces Target Price $50
Wolfe Research analyst Doug Schenkel upgrades $Qiagen NV(QGEN.US)$ to a buy rating, and sets the target price at $50.According to TipRanks data, the analyst has a success rate of 65.6% and a total ave
FDA Approves Bristol Myers Squibb's Combination Therapy For Colorectal Cancer Patients With Certain Type Of Gene Mutation
Friday, the FDA granted accelerated approval to Bristol Myers Squibb & Co's (NYSE:BMY) Krazati (adagrasib) in combination with cetuximab as a targeted treatment option for adult patients with KRASG12C